Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)
Top drug from Sanofi’s $1.5B Kymab buyout aces PhIIb in eczema
Two years ago, Sanofi CEO Paul Hudson made a bet on OX40L as an anti-inflammatory target when he bought out Kymab for $1.5 billion. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
